[Bio E-Stock] Shinpoong Pharmaceutical Shakes Off ‘Pyramax Failure’ and Accelerates Phase 3 Trials for New Stroke Drug… Faces ‘Deep Mountains’ of Price Cuts and Financial Burdens

조선일보

Lean Right

Factuality

Ownership

Shinpoong Pharmaceutical, which is developing a new stroke drug, is accelerating patient recruitment for Phase 3 clinical trials. With its financial capacity partially restored following a turnaround to profitability last year, the company appears to be once again driving the commercialization of its new drug pipeline. However, with the government signaling the implementation of a policy to lower generic drug prices this coming July, a deteriora…